Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27847 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Yan-Dong Su und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Mesothelioma, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
To explore the most effective adjuvant chemotherapy regimen for malignant peritoneal mesothelioma (MPM) through patient derived tumor‐like cell clusters (PTC) drug sensitivity test.
Methods
PTC were cultured in vitro with intraoperative specimens, and drug sensitivity test was performed to calculate the most effective chemotherapy regimen for MPM. The patients were divided into conventional and individualized chemotherapy group according to whether they received PTC drug testing. Univariate and multivariate analyses were conducted to identify independent prognostic factors.
Results
Among 186 MPM patients included, 63 underwent PTC culture and drug sensitivity test. The results showed that the most effective chemotherapy regimen was oxaliplatin + gemcitabine. After propensity score matching, a total of 64 patients were enrolled in the following study, including 32 patients receiving individualized chemotherapy guided by PTC drug results as group 1 and 32 patients receiving conventional chemotherapy as group 2. Survival analysis showed that the median OS of group 1 was not reached, significantly longer than that of group 2 (23.5 months) ( p < 0.05).
Conclusions
Compared with conventional chemotherapy, individualized chemotherapy guided by PTC drug sensitivity tests can prolong patient survival, and oxaliplatin + gemcitabine + apatinib could be the optimal adjuvant treatment regimen for MPM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
- Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Su, Y. D., Ma, R., Fu, Y. B., Wu, H. L., Liang, X. L., Liu, Y. T., Yu, Y., Yang, Z. R., & Li, Y. (2024). Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27847
Vancouver
Su YD, Ma R, Fu YB, Wu HL, Liang XL, Liu YT, et al. Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27847
BibTeX
@article{Su2024,
author = {Su, Yan-Dong and Ma, Ru and Fu, Yu-Bin and Wu, He-Liang and Liang, Xin-Li and Liu, Yi-Tong and Yu, Yang and Yang, Zhi-Ran and Li, Yan},
title = {Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27847}
}
EUVIMED